Glaukos Corporation to Release Second Quarter 2021 Financial Results after Market Close on August 5

Rhea-AI Summary

Glaukos Corporation (NYSE: GKOS) will announce its second quarter 2021 financial results on August 5, 2021, after market close. The management team will host a conference call and webcast at 1:30 p.m. PDT to discuss the results. Interested parties can access the live webcast via the company’s investor relations website and participate in the call by dialing the provided numbers and entering the conference ID. Glaukos specializes in innovative therapies for ocular conditions, including glaucoma and corneal disorders, having pioneered Micro-Invasive Glaucoma Surgery.

Positive

• Expected to release Q2 2021 financial results, indicating ongoing financial operations.
• Management will provide insights during a conference call, allowing investor engagement.

Negative

• None.

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2021 financial results after the market close on Thursday, August 5, 2021. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PDT (4:30 p.m. EDT) on August 5, 2021.

A link to the live webcast will be available on the company’s website at http://investors.glaukos.com. To participate in the conference call, please dial 833-231-8262 (U.S.) or 647-689-4107 (International) and enter Conference ID 4248858. A replay will be archived on the company’s website following completion of the call.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent^®, its first MIGS device, in the United States in 2012, its next-generation iStent inject^® device in the United States in 2018, and most recently, the iStent inject W device in 2020. In corneal health, Glaukos’ proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210715005772/en/

FAQ

When will Glaukos (GKOS) release its Q2 2021 financial results?

Glaukos is set to release its Q2 2021 financial results on August 5, 2021, after market close.

What time is the Glaukos (GKOS) conference call for Q2 2021 results?

The conference call will take place at 1:30 p.m. PDT (4:30 p.m. EDT) on August 5, 2021.

How can I listen to Glaukos (GKOS) Q2 2021 earnings call?

You can listen to the earnings call by accessing the live webcast on Glaukos' investor relations website.

What is the focus of Glaukos Corporation's business?

Glaukos focuses on novel therapies for glaucoma, corneal disorders, and retinal diseases.